Literature DB >> 12499715

Seizures in cerebral vein and dural sinus thrombosis.

J M Ferro1, M Correia, M J Rosas, A N Pinto, G Neves.   

Abstract

To describe early symptomatic and late seizures in a cohort of patients with acute cerebral vein and dural sinus thrombosis (CVDST) and to identify their determinants, we performed a prospective registry and follow-up study of CVDST patients admitted to 20 Portuguese hospitals, from June 1995 to June 1998. Of 91 registered patients, 31 (34%) had early symptomatic seizures; 29 (31.9%) as a presenting feature and 2 (2.1%) after admission. Early symptomatic seizures were more frequent in patients with motor and sensory deficits and in those with focal oedema/ischaemic infarcts or haemorrhages on admission CT/MR. On multivariate logistic regression analysis, sensory defects (OR = 7.8; 95% CI = 0.8-74.8) and a parenchymal lesion on admission CT/MR (OR = 3.7, 95% CI = 1.4-9.4) were found to be significant predictors of early symptomatic seizures. Seizures were directly related to acute death in 2 patients. Eight (9.5%) patients had late seizures, which were multiple in 4 (4.8%). Late seizures were more frequent in patients with early symptomatic seizures and with haemorrhage on admission CT/MR. Neither early symptomatic seizures nor late seizures were related to functional prognosis at the last follow-up (median = 1 year). There is a moderate risk of seizure recurrence early in the course and during the first year after CVDST. Seizures can be a cause of acute death, but might not have an independent influence on functional outcome. Pharmacological prevention of seizures after CVDST should probably be limited to patients with early symptomatic seizures and cerebral lesions on admission CT/MR. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12499715     DOI: 10.1159/000067133

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  28 in total

Review 1.  Intracerebral hemorrhage from cerebral venous thrombosis.

Authors:  Jitphapa Pongmoragot; Gustavo Saposnik
Journal:  Curr Atheroscler Rep       Date:  2012-08       Impact factor: 5.113

Review 2.  [Current controversies in the diagnosis and management of cerebral venous and dural sinus thrombosis].

Authors:  S Schwarz; M Daffertshofer; T Schwarz; D Georgiadis; R W Baumgartner; M Hennerici; C Groden
Journal:  Nervenarzt       Date:  2003-08       Impact factor: 1.214

3.  [Clinical course of cerebral sinus venous thrombosis. Data from a monocentric cohort study over 15 years].

Authors:  C Geisbüsch; C Lichy; D Richter; C Herweh; W Hacke; S Nagel
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

Review 4.  Acute Symptomatic Seizures and Provoked Seizures: to Treat or Not to Treat?

Authors:  Nisali Gunawardane; Madeline Fields
Journal:  Curr Treat Options Neurol       Date:  2018-08-23       Impact factor: 3.598

Review 5.  Cerebral venous thrombosis.

Authors:  Suzanne M Silvis; Diana Aguiar de Sousa; José M Ferro; Jonathan M Coutinho
Journal:  Nat Rev Neurol       Date:  2017-08-18       Impact factor: 42.937

6.  Cerebral venous sinus thrombosis complicated by seizures.

Authors:  Halil Onder
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

7.  Treatment of seizures in the neurologic intensive care unit.

Authors:  Panayiotis N Varelas; Marek Mirski
Journal:  Curr Treat Options Neurol       Date:  2007-03       Impact factor: 3.598

Review 8.  Cerebral vein thrombosis.

Authors:  Francesco Dentali; Walter Ageno
Journal:  Intern Emerg Med       Date:  2009-12-01       Impact factor: 3.397

Review 9.  Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis.

Authors:  Michelle Price; Albrecht Günther; Joseph S K Kwan
Journal:  Cochrane Database Syst Rev       Date:  2016-04-21

Review 10.  Poststroke epilepsy: epidemiology, pathophysiology and management.

Authors:  José M Ferro; Francisco Pinto
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.